Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Pedersen DD, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Lund Hetland M. Glintborg B, et al. Among authors: grydehoj j. Ann Rheum Dis. 2020 Apr;79(4):e37. doi: 10.1136/annrheumdis-2018-214952. Epub 2019 Jan 23. Ann Rheum Dis. 2020. PMID: 30674476 No abstract available.
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehøj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sørensen MV, Andersen LS, Grøn KL, Krogh NS, Pedersen L, Hetland ML; all departments of rheumatology in Denmark. Glintborg B, et al. Among authors: grydehoj j. Ann Rheum Dis. 2017 Aug;76(8):1426-1431. doi: 10.1136/annrheumdis-2016-210742. Epub 2017 May 4. Ann Rheum Dis. 2017. PMID: 28473425
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: grydehoj j. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5. Ann Rheum Dis. 2019. PMID: 30396903
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: grydehoj j. Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20. Ann Rheum Dis. 2020. PMID: 30573653 No abstract available.
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.
Glintborg B, Georgiadis S, Loft AG, Linauskas A, Lindegaard H, Hendricks O, Jensen DV, Andersen BL, Danebod K, Villumsen A, Eng G, Wiell C, Manilo N, Kristensen S, Raun J, Grydehøj J, Chrysidis S, Nørgaard M, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: grydehoj j. Ann Rheum Dis. 2020 Jun;79(6):846-848. doi: 10.1136/annrheumdis-2019-216702. Epub 2020 Feb 28. Ann Rheum Dis. 2020. PMID: 32111583 No abstract available.
Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS, Østergaard M, Jensen J, Zanjani L, Laursen T, Butt S, Dam MY, Lindegaard HM, Espesen J, Hendricks O, Kumar P, Kincses A, Larsen LH, Andersen M, Næser EK, Jensen DV, Grydehøj J, Unger B, Dufour N, Sørensen V, Vildhøj S, Hansen IM, Raun J, Krogh NS, Hetland ML. Jørgensen TS, et al. Among authors: grydehoj j. Rheumatology (Oxford). 2015 Dec;54(12):2156-65. doi: 10.1093/rheumatology/kev216. Epub 2015 Jul 13. Rheumatology (Oxford). 2015. PMID: 26175471
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.
Ibfelt EH, Sørensen J, Jensen DV, Dreyer L, Schiøttz-Christensen B, Thygesen PH, Colic A, Raun JL, Manilo N, Rødgaard A, Poulsen UE, Rasmussen C, Hansen T, Unger B, Pelck R, Kincses A, Nordin H, Lorenzen T, Theibich A, Jensen Hansen IM, Espesen J, Grydehøj J, Holland-Fischer M, Loft AG, Hetland ML. Ibfelt EH, et al. Among authors: grydehoj j. Clin Epidemiol. 2017 Nov 29;9:627-632. doi: 10.2147/CLEP.S141438. eCollection 2017. Clin Epidemiol. 2017. PMID: 29238225 Free PMC article.
Levetiracetam in spinal cord injury pain: a randomized controlled trial.
Finnerup NB, Grydehøj J, Bing J, Johannesen IL, Biering-Sørensen F, Sindrup SH, Jensen TS. Finnerup NB, et al. Among authors: grydehoj j. Spinal Cord. 2009 Dec;47(12):861-7. doi: 10.1038/sc.2009.55. Epub 2009 Jun 9. Spinal Cord. 2009. PMID: 19506571 Clinical Trial.